Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Peripheral Nervous System Diseases 1Ototoxicity 1Breast Neoplasms 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Thioctic Acid × Clear all
NCT01313117 2014-10-02

Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy

Northwestern University

Phase 1/2 Completed
9 enrolled 7 charts
Breast

Breast Neoplasms, Peripheral Nervous System Diseases

NCT00477607 2014-03-07

Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin

VA Office of Research and Development

Phase 2/3 Completed
39 enrolled 11 charts

Ototoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡